CN104968340A - 治疗肝脏疾病或病状的用途和方法 - Google Patents

治疗肝脏疾病或病状的用途和方法 Download PDF

Info

Publication number
CN104968340A
CN104968340A CN201380067678.5A CN201380067678A CN104968340A CN 104968340 A CN104968340 A CN 104968340A CN 201380067678 A CN201380067678 A CN 201380067678A CN 104968340 A CN104968340 A CN 104968340A
Authority
CN
China
Prior art keywords
liver
diamidine
use according
pentamidine
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380067678.5A
Other languages
English (en)
Chinese (zh)
Inventor
F.拉夫纳利
P.法拉杜
P.科林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncozyme Pharma Inc
Original Assignee
Oncozyme Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncozyme Pharma Inc filed Critical Oncozyme Pharma Inc
Publication of CN104968340A publication Critical patent/CN104968340A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
CN201380067678.5A 2012-12-21 2013-12-20 治疗肝脏疾病或病状的用途和方法 Pending CN104968340A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261745011P 2012-12-21 2012-12-21
US61/745,011 2012-12-21
PCT/CA2013/051003 WO2014094176A1 (en) 2012-12-21 2013-12-20 Uses and methods for the treatment of liver diseases or conditions

Publications (1)

Publication Number Publication Date
CN104968340A true CN104968340A (zh) 2015-10-07

Family

ID=50977490

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380067678.5A Pending CN104968340A (zh) 2012-12-21 2013-12-20 治疗肝脏疾病或病状的用途和方法

Country Status (12)

Country Link
US (2) US9375411B2 (enExample)
EP (1) EP2934501A4 (enExample)
JP (1) JP6370801B2 (enExample)
KR (1) KR20150126595A (enExample)
CN (1) CN104968340A (enExample)
AU (1) AU2013362755B2 (enExample)
BR (1) BR112015014836A2 (enExample)
CA (1) CA2894466A1 (enExample)
HK (1) HK1216721A1 (enExample)
MX (1) MX2015007945A (enExample)
RU (1) RU2015126505A (enExample)
WO (1) WO2014094176A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111448181A (zh) * 2017-11-16 2020-07-24 蒙特多力士有限公司 单脒和二脒核酸内切-外切酶抑制剂和抑制核酸内切-外切酶活性的方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111225686A (zh) * 2017-08-15 2020-06-02 普罗根尼蒂公司 使用可摄入装置释放免疫调节剂治疗炎性疾病
CN110478340A (zh) * 2018-05-14 2019-11-22 复旦大学 喷他嘧啶羟乙基磺酸盐在制备肝癌药物方面的应用
WO2021034727A1 (en) 2019-08-16 2021-02-25 Applied Molecular Transport Inc. Compositions, formulations, and interleukin production and purification

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162361A (en) * 1990-04-10 1992-11-10 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Method of treating diseases associated with elevated levels of interleukin 1
CN1829509A (zh) * 2003-07-28 2006-09-06 康宾纳特克斯公司 用于治疗肿瘤的药物组合

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA388674A (en) * 1940-05-14 The B. F. Goodrich Company Brake structure
GB1288376A (enExample) 1968-10-29 1972-09-06
DE2833135A1 (de) 1978-07-28 1980-02-07 Henkel Kgaa Verwendung von substituierten oligocarbamidinen als mikrobistatika sowie diese enthaltende antimikrobielle mittel
US5204113A (en) 1987-04-09 1993-04-20 Fisons Plc Pharmaceutical compositions containing pentamidine
US5084480A (en) 1987-11-06 1992-01-28 Fujisawa Usa, Inc. Pentamidine salts useful in the treatment of pneumocystis carinii pneumonia
US4853416A (en) 1988-04-25 1989-08-01 Fisons Corporation Solutions of pentamidine
DE4321444A1 (de) 1993-06-28 1995-01-05 Bernd Prof Dr Clement Pharmazeutische Zubereitung
JPH08333324A (ja) 1995-06-08 1996-12-17 Terumo Corp ベンゼン誘導体およびそれを含有する医薬製剤
JP3540457B2 (ja) 1995-09-11 2004-07-07 テルモ株式会社 抗血栓性を賦与した医療用基材
AU762523C (en) 1998-11-10 2004-02-12 Janssen Pharmaceutica N.V. HIV replication inhibiting pyrimidines
US7884090B2 (en) 1999-03-17 2011-02-08 Ernest L. Bonner, Jr. Compositions and methods for the treatment of arthritis
US7115665B1 (en) 2000-11-16 2006-10-03 Onocozyme Pharma, Inc. Inhibitors of endo-exonuclease activity for treating cancer
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US6693125B2 (en) 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
CA2459793A1 (en) 2001-09-07 2003-08-28 The Cleveland Clinic Foundation Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases
US20040010045A1 (en) 2001-09-07 2004-01-15 Taolin Yi Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
WO2003092616A2 (en) * 2002-05-01 2003-11-13 The Cleveland Clinic Foundation Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
US7994225B2 (en) 2004-03-17 2011-08-09 Rempex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections
WO2005089738A2 (en) 2004-03-17 2005-09-29 Mpex Pharmaceuticals, Inc. Use and administration of bacterial efflux pump inhibitors
WO2007001455A2 (en) 2004-11-12 2007-01-04 Mediquest Therapeutics, Inc. Hydrophobic polyamine amides as potent lipopolysaccharide sequestrants
TW200719903A (en) 2005-04-19 2007-06-01 Combinatorx Inc Compositions for the treatment of neoplasms
US7199267B1 (en) 2005-10-21 2007-04-03 Mediquest Therapeutics, Inc. Recognition of oligiosaccaride molecular targets by polycationic small molecule inhibitors and treatment of immunological disorders and infectious diseases
US20070197658A1 (en) 2006-02-22 2007-08-23 David Sunil A Polyamines and their use as antibacterial and sensitizing agents
US20080226596A1 (en) 2006-06-19 2008-09-18 Taolin Yi Therapeutic compositions and methods useful in treating hepatitis
DE102008007426A1 (de) 2008-02-01 2009-08-06 Rheinische Friedrich-Wilhelms-Universität Bonn Unbenetzbare Oberflächen
DE102008007381A1 (de) * 2008-02-01 2009-08-13 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Amidine und Guanidine und deren Derivate zur Behandlung von Krankheiten
US8436049B2 (en) 2008-02-21 2013-05-07 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Uses of pentamidine and related compounds
JP2012525371A (ja) * 2009-05-01 2012-10-22 オンコザイム・ファーマ・インコーポレイテッド 癌を治療するためのペンタミジンの組み合わせ
WO2011035225A1 (en) 2009-09-21 2011-03-24 President And Fellows Of Harvard College Synergistic combination therapy
US20130244963A1 (en) 2010-09-30 2013-09-19 Portola Pharmaceuticals, Inc. Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide
SI2550963T1 (sl) * 2011-07-25 2017-05-31 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Estri amidoksim karboksilne kisline pentamidina kot predzdravila in njihova uporaba kot zdravila
WO2014009592A1 (en) * 2012-07-11 2014-01-16 Waterbox Oy Apparatus for providing rotating movement

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162361A (en) * 1990-04-10 1992-11-10 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Method of treating diseases associated with elevated levels of interleukin 1
CN1829509A (zh) * 2003-07-28 2006-09-06 康宾纳特克斯公司 用于治疗肿瘤的药物组合

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111448181A (zh) * 2017-11-16 2020-07-24 蒙特多力士有限公司 单脒和二脒核酸内切-外切酶抑制剂和抑制核酸内切-外切酶活性的方法
CN111448181B (zh) * 2017-11-16 2023-05-19 蒙特多力士有限公司 单脒和二脒核酸内切-外切酶抑制剂和抑制核酸内切-外切酶活性的方法
US12239617B2 (en) 2017-11-16 2025-03-04 Montdorex Inc. Mono- and di-amidine endo-exonuclease inhibitors and methods for inhibiting endo-exonuclease activity

Also Published As

Publication number Publication date
JP2016503035A (ja) 2016-02-01
KR20150126595A (ko) 2015-11-12
AU2013362755A1 (en) 2015-07-02
EP2934501A4 (en) 2016-06-01
HK1216721A1 (zh) 2016-12-02
EP2934501A1 (en) 2015-10-28
JP6370801B2 (ja) 2018-08-08
US20160287535A1 (en) 2016-10-06
RU2015126505A (ru) 2017-01-27
US9375411B2 (en) 2016-06-28
US9827211B2 (en) 2017-11-28
AU2013362755B2 (en) 2018-09-13
WO2014094176A1 (en) 2014-06-26
CA2894466A1 (en) 2014-06-26
MX2015007945A (es) 2016-02-16
BR112015014836A2 (pt) 2017-07-11
US20150297540A1 (en) 2015-10-22

Similar Documents

Publication Publication Date Title
CN1276754C (zh) 胃肠基质肿瘤的治疗
JP6931004B2 (ja) ２−ブロモ−１−（３，３−ジニトロアゼチジン−１−イル）エタノンの静脈内投与のための組成物および方法
CN106456626B (zh) 喹啉衍生物用于治疗软组织肉瘤的方法和用途以及用于治疗软组织肉瘤的药物组合物
CN102421427B (zh) 用于治疗特定癌症的包含rdea119/bay869766的药物组合
EP2785349A1 (en) Combination treatment of cancer
TW201919617A (zh) 用於治療卵巢癌的化合物
TW202320758A (zh) 組合
TW202333675A (zh) 用於治療癌症之組合療法之用途
US9827211B2 (en) Uses and methods for the treatment of liver diseases or conditions
CN102438608A (zh) 包含ave8062和索拉非尼的抗肿瘤组合
JP5340393B2 (ja) 腎細胞癌の治療のための３，３’，４，４’−テトラヒドロキシ−２，２’−ビピリジン−ｎ，ｎ’−ジオキシド
WO2017148129A1 (zh) 一种用于治疗恶病质的药物组合物及其应用
JP2009539916A (ja) ステージＩＶの悪性黒色腫の処置のための医薬品の製造のためのチモシンα１の使用
CN115038447A (zh) 用于治疗癌症的组合疗法
WO2019242688A1 (zh) 3-羟基氨基苯甲酸与索拉非尼联合用药治疗肿瘤
CN117442704A (zh) 一种治疗前列腺癌的药物组合及其应用
TW202308641A (zh) 用於治療癌症之方法及包含cdk抑制劑之給藥方案
US20100087398A1 (en) Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions
CN115190800A (zh) 一种brd4抑制剂的用途
US20060264388A1 (en) Method for treating liver cancer by intrahepatic administration of nemorubicin
CN112533604A (zh) 用于治疗癌症的组合疗法
WO2020205608A1 (en) Uses of androgen receptor antagonists and jnk pathway inhibitors, and pharmaceutical compositions related thereto
JP2005520806A (ja) がん治療を改善する併用療法におけるキナゾリノン化合物
CN113271935A (zh) 用替司他赛治疗cns肿瘤的方法
HK40040830A (en) Combination therapy for treating cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20151007

RJ01 Rejection of invention patent application after publication